Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06447025 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
A Phase 2 study, sponsored by Larimar Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT06447025 is a Phase 2 study that is actively recruiting participants, run by Larimar Therapeutics. The registered enrollment target is 85 participants.
The verdict
NCT06447025, a Phase 2 study, is actively recruiting participants, sponsored by Larimar Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and adults with FRDA who have not participated in a prior clinical study of CTI-1601.
Interventions
- DRUG CTI-1601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2024-01-25 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06447025
The ClinicalTrials.gov registry entry for NCT06447025 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Larimar Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTI-1601 is the first listed.
NCT06447025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06447025 about?
NCT06447025 is a clinical study titled "An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia". An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and a...
What is the current status of trial NCT06447025?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2024-01-25. Estimated completion is 2027-01.
What interventions are being tested in trial NCT06447025?
The interventions under investigation include: CTI-1601 (DRUG).
Who is sponsoring clinical trial NCT06447025?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.